Agenda

2nd NCI MDS Symposium 

This will be a virtual meeting with three pre-recorded presentation blocks and live panel discussions at the end of each section.

 

Friday, February 25, 2022

01:00 pm - 01:10 pm EST
Welcome and Introductions

Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
Sung-Yun Pai, M.D., Center for Cancer Research, NCI
Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute, NIH

Session 1: Keynote Speakers

01:10 pm - 01:25 pm EST
The Status of Myelodysplastic Syndromes


Mikkael Sekeres, M.D., University of Miami Health System

01:25 pm - 01:35 pm EST
MDS Classifications

Katherine Calvo, M.D., Ph.D., Clinical Center, NIH

01:35 pm - 01:45 pm EST
Alterations in Gene Expression in MDS

Daniel Larson, Ph.D., Center for Cancer Research, NCI

01:45 pm - 01:55 pm EST
Preclinical Models for MDS

Peter Aplan, M.D., Center for Cancer Research, NCI

01:55 pm - 02:05 pm EST
Translational Genomics in Myeloid Malignancies

Laura Dillon, Ph.D., National Heart, Lung, and Blood Institute, NIH

02:05 pm - 02:20 pm EST
Questions & Answers

Moderators:

Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute, NIH
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI

Session 2:  Natural History Studies

02:20 pm - 02:25 pm EST
The Natural History and Biospecimen Acquisition Protocol for Myelodysplastic Syndromes

Kathy McGraw, Ph.D., Center for Cancer Research, NCI

02:25 pm - 02:30 pm EST
CHIP/CCUS Natural History Protocol

Emma Groarke, M.D., National Heart, Lung, and Blood Institute, NIH

02:30 pm - 02:35 pm EST
Longitudinal Studies of Patients with FPDMM and Germline RUNX1 Mutations

Paul Liu, Ph.D., National Human Genome Research Institute, NIH

Session 3:  Treatments for Inherited Predispositions

02:35 pm - 02:40 pm EST
Phase Ib Study of Imatinib Treatment for RUNX1 Activity Improvement in RUNX1 Deficiency  Patients

Lea Cunningham, M.D., Center for Cancer Research, NCI

02:40 pm - 02:45 pm EST
A Phase I/II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with VEXAS Syndrome

Bhavisha Patel, M.D., National Heart, Lung, and Blood Institute, NIH

02:45 pm - 02:50 pm EST
Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency

Danielle Arnold, M.D., Center for Cancer Research, NCI

02:50 pm - 02:55 pm EST
Break

Session 4:  Molecular Targeting of High Risk and Low Risk MDS

02:55 pm - 03:00 pm EST
A Phase I/II Trial of BMS-986253 (anti-IL8) with or without DNMTi in Myelodysplastic Syndromes

Noa Holtzman, M.D., Center for Cancer Research, NCI

03:00 pm - 03:05 pm EST
A Phase I/II Trial of Eltanexor (KPT-8602) with Decitabine-Cedazuridine in Myelodysplastic Syndromes

Nina Kim, M.D., Center for Cancer Research, NCI

03:05 pm - 03:10 pm EST
Phase I/II Trial of pacritinib in Adults and Children 12 Years of Age or Greater with Myelodysplastic Syndromes or Myelodysplastic/myeloproliferative Neoplasms

Jacqui Klicka-Skeels, M.D., Center for Cancer Research, NCI

Session 5:  Cellular Therapy Protocols

03:10 pm - 03:15 pm EST
CD33 CART

Nirali Shah, M.D., M.H.Sc, Center for Cancer Research, NCI

03:15 pm - 03:20 pm EST
Autologous CD123-ENG T Cells for AML/MDS

Challice Bonifant, M.D., Ph.D., Johns Hopkins Medicine

03:20 pm - 03:25 pm EST
Development of T Cell-Based Immunotherapy for Hematologic Malignancies

Vid Leko, M.D., Center for Cancer Research, NCI

Session 6:  Transplantation Protocols

03:25 pm - 03:30 pm EST
VOR CD33

Nirali Shah, M.D., M.H.Sc, Center for Cancer Research, NCI

 

03:30 pm - 03:35 pm EST
Hematopoietic Cell Transplantation (HCT) for Patients with Myelodysplastic Syndrome

Christopher Kanakry, M.D, Center for Cancer Research, NCI

03:35 pm - 03:40 pm EST
Geriatric Assessment for Hematopoietic Cell Transplantation

Shannon McCurdy, M.D., University of Pennsylvania

03:40 pm - 03:45 pm EST
Phase I/II Study of Pacritinib, a JAK2/IRAK1/CSF1R/FLT3 Inhibitor in Refractory Chronic GVHD after HSCT

Noa Holtzman, M.D., Center for Cancer Research, NCI

03:45 pm - 04:00 pm EST
Questions and Answers

Moderators:

Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute, NIH
Daniel Larson, Ph.D., Center for Cancer Research, NCI
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI

 

04:00 pm - 04:05 pm EST
Wrap-Up and Adjourn